Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer’s Disease

World News: . []

Merck NYSE MRK known as MSD outside the United States and Canada today announced that it will be stopping protocol 019 also known as the APECS study a Phase 3 study evaluating verubecestat MK-8931 an investigati onal sm...

More news and information about Merck

Published By:

Business Wire: 21:30 GMT Tuesday 13th February 2018

Published: .

Search for other references to "merck" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us